Business Wire

Heubach Partners with SK Capital to Drive Next Phase of Growth for Clariant’s Pigments Business

14.6.2021 08:30:00 EEST | Business Wire | Press release

Share

The Heubach Group (“Heubach”), in partnership with SK Capital Partners (“SK Capital”), announced today a definitive agreement to acquire Clariant’s Pigments Business (“Clariant Pigments”). The combined business will operate under the Heubach name, creating a global pigments leader generating more than €900 million in annual sales.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210613005051/en/

The transaction values Clariant Pigments at approximately CHF 805 million, with additional consideration of CHF 50 million contingent on the 2021 financial performance of the business unit. As part of the transaction, Clariant will be reinvesting for a minority stake in the combined business, demonstrating its continuing commitment to the success of Clariant Pigments and the substantial growth opportunity in the combination with Heubach.

Heubach is a leading global producer of organic, inorganic, and non-toxic anti-corrosive pigments, operating four global production locations and employing approximately 1,000 people. Clariant Pigments is a leading global provider of organic pigments, pigment preparations and dyes, operating 13 global production sites and employing approximately 1,900 people.

The combination of Heubach and Clariant Pigments is expected to be highly synergistic, and creates a diversified pigments player that will enhance Heubach’s and Clariant Pigments existing positions. The businesses share a complementary product portfolio and a regionally compatible asset footprint, which will allow for an expanded product range and wider geographical coverage to better serve customers. The combined business will continue to prioritize innovation, quality, technical service and product development in order to provide an enhanced value proposition for its customers.

Johann Heubach, Chief Executive Officer of the Heubach Group, noted “We have been in pigments for more than 200 years. My late father and I set out to drive consolidation in the pigments industry, and the combination of Heubach and Clariant Pigments is a major milestone in this vision. We are extremely excited to have gained SK Capital as a partner and we are eagerly looking forward to capitalizing on their expertise in integrating and operating businesses in the global chemical industry. The fit between Heubach and Clariant Pigments is perfect. The combination of industry leading technologies, a product portfolio serving a wide range of customer requirements and global production and service footprint will give the newly formed Heubach Group the ability to serve our global customer base in the coatings, plastics, inks and specialty applications fields with industry leading products and services.”

Aaron Davenport, a Managing Director of SK Capital, noted “Clariant Pigments is a premier global colorant solutions provider, and, together with our new partners, the Heubach Group and Clariant, we see a tremendous opportunity to create significant value for all stakeholders.”

Conrad Keiijzer, Chief Executive Officer of Clariant, noted “We are pleased to announce the agreement with Heubach and SK Capital for the sale of our pigments business. We are confident that with Heubach and SK Capital, we have found the right new owners of this business, for our customers, our colleagues and our other stakeholders.”

Closing of the transaction is subject to customary conditions and approvals and is expected to take place in the first half of 2022. The Valence Group of Piper Sandler & Co., BofA Securities and Citi served as financial advisors to Heubach and SK Capital. Committed financing for the transaction was provided by BofA Securities and Citi. Lenz & Staehelin AG and Kirkland & Ellis LLP acted as legal counsel to Heubach and SK Capital. Milbank LLP acted as legal counsel to Heubach. Homburger AG acted as legal counsel to Clariant and Deutsche Bank AG served as Clariant’s financial advisor.

About Heubach Group

Heubach has more than 200 years of experience in pigments production as one of the first-ever manufacturers of pigments. Heubach is a leading global producer of organic, inorganic and anticorrosive pigments and pigment preparations, is headquartered in Langelsheim, Germany and has sites in Germany, US, and India with sales offices around the world. Over the years, Heubach has developed a leading technology position, which has been built both internally and from the successful take-overs of pigment activities from Bayer, DuPont and ICI. Heubach operates its global business according to “Best-in-Class” German standards with a focus on EHS excellence, quality leadership, product stewardship and innovation. For more information, please visit www.heubachcolor.com.

About SK Capital

SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $11 billion annually, employs more than 16,000 people globally and operates 150 plants in 28 countries. The firm currently has greater than $5 billion of assets under management. For more information, please visit www.skcapitalpartners.com.

About Clariant

Clariant is a focused and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2020, the company employed a total workforce of 13,235. In the financial year 2020, Clariant recorded sales of CHF 3.860 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Europe
Stephen Fishleigh
BackBay Communications
+44 203 475 7552 (o)
+44 7904 114 002 (m)
stephen.fishleigh@backbaycommunications.com

United States
Jeremy Milner
BackBay Communications
401-862-9422
jeremy.milner@backbaycommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 08:00:00 EEST | Press release

Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706426842/en/ Key findings:1 Nine out of ten people globally are affected by skin quality concerns, with each person experiencing an average of two concerns in the past month The most common concerns are fine lines and wrinkles (41%), dry skin (40%), and dull skin (37%), most frequently affecting the face Skin quality impacts quality of life for 85% of people, with more than one in three reporting feelings of self-consciousness, insecurity or anxiety Skin

Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 05:00:00 EEST | Press release

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing awareness of the connection between the gut and the brain, commonly referred to as the gut–brain axis. As a result, the g

Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 03:00:00 EEST | Press release

Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release

Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye